	US 12,460,182 B2
	Cell-containing pharmaceutical composition
Takayuki Asahara, Kanagawa (JP); Amankeldi A. Salybekov, Kanagawa (JP); and Makoto Seki, Tokyo (JP)
Assigned to CellAxia Inc., Tokyo (JP)
Appl. No. 17/612,441
Filed by CellAxia Inc., Tokyo (JP)
PCT Filed Aug. 19, 2019, PCT No. PCT/JP2019/032322 § 371(c)(1), (2) Date Nov. 18, 2021, PCT Pub. No. WO2021/033247, PCT Pub. Date Feb. 25, 2021.
Prior Publication US 2022/0218744 A1, Jul. 14, 2022
Int. Cl. C12N 5/0786 (2010.01); A61K 40/10 (2025.01); A61K 40/17 (2025.01); A61K 40/22 (2025.01); A61K 40/24 (2025.01); A61K 40/41 (2025.01); A61P 29/00 (2006.01)

CPC C12N 5/0645 (2013.01) [A61K 40/10 (2025.01); A61K 40/17 (2025.01); A61K 40/22 (2025.01); A61K 40/24 (2025.01); A61K 40/416 (2025.01); A61P 29/00 (2018.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); C12N 2500/90 (2013.01)]

5 Claims

1. A method for the treatment of an inflammatory disease, comprising administering an effective amount of cell population enriched in M2 macrophage to a target in need thereof, wherein the cell population comprises the M2 macrophage in a proportion of not less than 7%.